biostudies-literatureUnknown17(1)Seijari MN<h4>Introduction</h4>Primary splenic lymphoma is a rare lymphoproliferative disorder that involves the spleen, exhibits diverse clinical presentations, and lacks a clear consensus in terms of management strategies.<h4>Case presentation</h4>We present the case of a 52-year-old patient with a complex medical history marked by multiple chronic medical conditions. The patient was diagnosed with primary splenic lymphoma, specifically the diffuse large B-cell subtype. Treatment for our patient involved a shortened course of chemotherapy (4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] followed by two doses of rituximab) due to issues related to compliance and treatment-related complications. This was followed by consolidative radiotherapy without resorting to splenectomy.<h4>Conclusion</h4>Remarkably, despite using a shortened course of R-CHOP, the patient achieved complete resolution, and a positron emission tomography scan conducted at the end of the 6-month posttreatment period confirmed sustained complete remission.Case reports in oncology447-453https://www.ebi.ac.uk/biostudies/studies/S-EPMC10919911biostudies-literaturePrimary Splenic Diffuse Large B-Cell Lymphoma: A Case Report and Literature Review of a Rare Condition.PMC10919911Seijari MNElfaieg AElkourashy SAKaspo SAlshurafa AfalsePrimary Splenic Diffuse Large B-Cell Lymphoma: A Case Report and Literature Review of a Rare Condition.<h4>Introduction</h4>Primary splenic lymphoma is a rare lymphoproliferative disorder that involves the spleen, exhibits diverse clinical presentations, and lacks a clear consensus in terms of management strategies.<h4>Case presentation</h4>We present the case of a 52-year-old patient with a complex medical history marked by multiple chronic medical conditions. The patient was diagnosed with primary splenic lymphoma, specifically the diffuse large B-cell subtype. Treatment for our patient involved a shortened course of chemotherapy (4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] followed by two doses of rituximab) due to issues related to compliance and treatment-related complications. This was followed by consolidative radiotherapy without resorting to splenectomy.<h4>Conclusion</h4>Remarkably, despite using a shortened course of R-CHOP, the patient achieved complete resolution, and a positron emission tomography scan conducted at the end of the 6-month posttreatment period confirmed sustained complete remission.2024-01-01T00:00:00Z2024 Jan-Dec2025-04-04T12:34:50.186Z2025-04-04T12:34:50.186ZS-EPMC109199113845571610.1159/000537780